We are doing this study to compare the usual treatment with hormonal therapy medications to treatment with low-dose tamoxifen. We want to know which option has better outcomes for people with low-risk early-stage breast cancer.

Low-Risk Early-Stage Breast Cancer

Adults ages 18+ who:

• Are diagnosed with unilateral invasive breast adenocarcinoma
• Have HER2 negative disease
• Are ER+ in at least 10% of cells
• Have no evidence of metastases (spread)

For more information, contact the study team at nick.jeffries@duke.edu.

If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 groups:

• Group 1: If you are in this group, you will get the usual drug used to treat this type of cancer, either anastrozole, letrozole, exemestane, or tamoxifen 20 mg/day, decided by you and your physician. You will take one of these hormonal therapy drugs as a pill you take by mouth every day for a total of 5 years.
• Group 1: If you are in this group, you will get tamoxifen that is prescribed at a lower dose. You will take this hormonal therapy as a pill you take by mouth every other day for a total of 5 years.